SHSE:600713 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SHSE:600713 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nanjing Pharmaceutical Co's Long-Term Debt for the quarter that ended in Mar. 2024 was ¥3,483 Mil.
Nanjing Pharmaceutical Co's quarterly Long-Term Debt increased from Sep. 2023 (¥2,110 Mil) to Dec. 2023 (¥2,118 Mil) and increased from Dec. 2023 (¥2,118 Mil) to Mar. 2024 (¥3,483 Mil).
Nanjing Pharmaceutical Co's annual Long-Term Debt declined from Dec. 2021 (¥2,628 Mil) to Dec. 2022 (¥2,222 Mil) and declined from Dec. 2022 (¥2,222 Mil) to Dec. 2023 (¥2,118 Mil).
The historical data trend for Nanjing Pharmaceutical Co's Long-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Long-Term Debt | Get a 7-Day Free Trial | - | 1,026.98 | 2,628.40 | 2,221.65 | 2,117.78 |
Nanjing Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Long-Term Debt | Get a 7-Day Free Trial | 2,300.16 | 3,302.91 | 2,109.77 | 2,117.78 | 3,482.93 |
Nanjing Pharmaceutical Co (SHSE:600713) Long-Term Debt Explanation
Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.
Thank you for viewing the detailed overview of Nanjing Pharmaceutical Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Xiao Hong | senior management | |
Peng Yu Ping | senior management | |
She Ping | Supervisors | |
Jiang Xiao Jun | senior management | |
Teng Xue Wu | senior management | |
Zhou Jian Jun | senior management | |
Li Yi | Director | |
Huang Yan Li | Supervisors | |
Tang Jian Zhong | senior management | |
Zhang Yan Hui | senior management | |
Zhou Yao Ping | Director | |
Wang Hui Qing | senior management | |
He Jin Geng | senior management | |
Ding Feng Jun | Director | |
Liang Yu Tang | Director |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.